Nevro’s SCS system delivers long-term relief with spinal cord stimulation

Nevro announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain – NSRBP – multicenter randomized controlled trial in the Journal of Neurosurgery: Spine. The published 24-month data evaluated outcomes for NSRBP patients treated with Nevro’s high-frequency spinal cord stimulation – SCS – system plus conventional medical management – CMM – versus CMM alone. The data show that patients in the high-frequency SCS arm experienced profound improvements in pain, function, and quality of life, plus reduced opioid use compared to the CMM arm at 24 months. The long-term data provides further evidence of the benefits of high-frequency SCS in managing patients with NSRBP. 81.6% of all patients who received a permanent implant were classified as pain responders – achieved greater than or equal to 50% pain relief – at 24 months, with 58.4% of patients classified as profound responders who achieved greater than or equal to 80% pain relief. Opioid usage was decreased or stopped in 62% percent of patients who were using opioids at baseline. No new safety signals were identified during the 24-month follow-up.